20 April 2022

ASX:GLH

Global Health Ltd March 2022

Quarterly Business Activity Report & Appendix 4C

Melbourne, Australia – Healthcare software provider Global Health Ltd (ASX: GLH) ("Global Health") is pleased to release its Appendix 4C Cash Flow Report for the quarter ended 31 March 2022, along with a Quarterly Business Activity Report.

The Financial Highlights are based on the unaudited management accounts for the quarter ended 31 March 2022.

Financial Highlights

- Growth in recurring revenues for the quarter continues as the organisation benefits from new customer sign-ups within the financial year
- Positive operating cashflow for the quarter driven by collections from large, contracted customers
- Strong balance sheet position, underpinned by a cash balance of \$6.92m and debt of \$0.19m
- Continued investment in Key Personnel and R&D remains consistent with our growth and expansionary plans
- M & A activity is constantly under review by the Board based on meeting key metrics that could ultimately see a 'best fit' for the Company

In accordance with Listing Rule 4.7C.1, the expenditures of Global Health for the quarter ended 31 March 2022 are set out in the table below:

Expense Category	Amount (\$A'000)
Product manufacturing and operating costs	702
Advertising and marketing	46
Leased Assets	40
Staff costs	1,221
Administration and corporate costs	238
Interest and other costs of finance paid	4
Research and product development	240
Purchase of property, plant and equipment	6
Repayment of borrowings (HP Finance)	33

In accordance with Listing Rule 4.7C.3, payments to related parties and their associates during the quarter totalled \$111K. This related to directors' remuneration.

Business Activity

The quarter has seen a significant increase in account management and customer engagement, including valuable, face-to-face visits as Covid restrictions ease. This has led to strengthening of relationships and accelerated use of new features and capabilities within our platforms. In addition, we have gleaned some valuable feedback on the customer experience journey and ways to further enhance usage and customer satisfaction levels.

The results of these activities, and follow-on work by Global Health on its platforms will drive an increased level of appeal for new customers, as well as a positive impact on retention rates and satisfaction levels of the current customer base.

Sales and marketing activity continues at a heightened pace and our pipeline continues to develop well.

Forward Outlook

The business is committed to developing and capitalising upon a number of key opportunities in our current pipeline. There is a continued investment focus on developing systems and features that improve our ability to appeal to current as well as new customers, in the pursuit of long-term growth.

Global Health will continue to execute on our strategy to accelerate growth, focussing on increasing our market share in three core areas, namely - **Community Health services**, **Hospitals and Mental Health**.

This announcement was approved for lodgement by the Board.

- ENDS

For further information please contact:

Michael Davies

Chief Executive Officer, Global Health Limited

M: 0429306650

E: Michael.davies@global-health.com

Rod North - Investor Relations, Media & PR

Managing Director, Bourse Communications

M: 0408 670 706

E: rod@boursecommunications.com.au

About Global Health Limited

Global Health (ASX: GLH) is a leading provider of Digital Health solutions to the Australian Healthcare Industry. Innovation, consumer-centricity and connectivity are the foundations of the Company's vision of 'Connecting Clinicians and Consumers.'

Global Health helps streamline the delivery of healthcare services and provide better health outcomes across various health sectors, including acute and community settings.

Global Health offers a range of bespoke software and SaaS solutions helping health businesses to be more efficient and deliver excellent patient care. These include electronic medical records for health delivery organisations, client management systems for community health, patient administration systems for hospitals, practice management systems, secure messaging for connected care, patient engagement platforms and consumer health records.

Located in Melbourne, Victoria the company is ISO27001 compliant.

Find out more about Global Health Solution's at www.global-health.com



Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Global Health Limited

ABN

Quarter ended ("current quarter")

75 091 377 892

31 March 2022

Cor	nsolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	2,275	5,654
1.2	Payments for		
	(a) research and development	-	-
	(b) product manufacturing and operating costs	(702)	(1,817)
	(c) advertising and marketing	(46)	(161)
	(d) leased assets	(40)	(93)
	(e) staff costs	(1,221)	(3,929)
	(f) administration and corporate costs	(238)	(658)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	-
1.5	Interest and other costs of finance paid	(4)	(15)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	24	(1,019)

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(6)	(8)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	(240)	(549)
2.2	Proceeds from disposal of:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-
	(j) investments	-	-
	(k) intellectual property	-	-
	(I) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	126	126
2.6	Net cash from / (used in) investing activities	120	(431)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	3,907
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	10	20
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(268)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(33)	(127)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(23)	3,532

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	7,041	4,840
4.2	Net cash from / (used in) operating activities (item 1.9 above)	24	(1,019)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(120)	(431)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(23)	3,532
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	6,922	6,922

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	6,922	7,041
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	6,922	7,041

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1 *	111
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
	f any amounts are shown in items 6.1 or 6.2, your quarterly activity report must included and in	ude a description of, and

* Payments associated with item 6.1 relate to directors' fees/directors' remuneration.

7.	Financing facilities Note: the term "facility" includes all forms of financing arrangements available to the entity.	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000	
	Add notes as necessary for an understanding of the sources of finance available to the entity.		•	
7.1	Loan facilities	-	-	
7.2	Credit standby arrangements	25	16	
7.3	Other (please specify)	175	175	
7.4	Total financing facilities	200	191	
7.5	Unused financing facilities available at qu	arter end	9	
7.6	Include in the box below a description of each facility above, including the lende interest rate, maturity date and whether it is secured or unsecured. If any addition financing facilities have been entered into or are proposed to be entered into aft quarter end, include a note providing details of those facilities as well.			
	7.2 Lender: Australia and New Zealand Bankir Company Credit Card Facility Interest rate: Up to 8-week Interest free pe purchases if unpaid by the due date. 19.2 Secured/unsecured: Unsecured	riod. Otherwise, 17.74	% per annum on	
	7.3			
	Lender: HP Financial Services (Australia) Pty Ltd			

Interest rate: 8.5% per annum Maturity date: June 2023

Secured/unsecured: Unsecured

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	24
8.2	Cash and cash equivalents at quarter end (item 4.6)	6,922
8.3	Unused finance facilities available at quarter end (item 7.5)	9
8.4	Total available funding (item 8.2 + item 8.3)	6,931
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
	Note: if the entity has reported positive net operating cash flows in item 1.9, answ Otherwise, a figure for the estimated quarters of funding available must be included.	•

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 20 April 2022

Authorised by: Board of Directors

Notes

- 1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
- 2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
- 4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
- 5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.